Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 May 21;96(10):1569-78.
doi: 10.1038/sj.bjc.6603770. Epub 2007 Apr 24.

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma

Y Lemos-González  1 , F J Rodríguez-Berrocal, O J Cordero, C Gómez, M Páez de la Cadena
Affiliations
Comparative Study

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma

Y Lemos-González et al. Br J Cancer. .

Abstract

Serum levels of the soluble epidermal growth factor receptor (sEGFR) and its ligands epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha) and amphiregulin (AR) were measured in healthy donors and patients with non-small cell lung cancer (NSCLC) and head and neck carcinoma (HNC). In NSCLC, we found sEGFR and EGF levels significantly lowered in patients with respect to healthy donors. In HNC patients, significantly diminished levels were found in the case of sEGFR, EGF and also AR. In both malignancies, no significant association was found between the serum levels of the molecules and the patients' gender, age or smoking habit. Only a significant association was found between the decrease of sEGFR and the absence of distant metastasis in NSCLC and the tumour stage in HNC. The most interesting result was that combining sEGFR and EGF, sensitivities of 88% in NSCLC and 100% in HNC were reached without losing specificity (97.8% in both cases). The use of discriminant analysis and logistic regression improved the sensitivity for NSCLC and the specificity for HNC. These data demonstrate a potentially interesting value of the serum levels of sEGFR and EGF, especially when combined, as markers for NSCLC and HNC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representation of (A) sEGFR levels (ng ml−1) in sera from 50 healthy donors, 25 patients with NSCLC and 50 HNC patients; (B) EGF levels (pg ml−1) in sera from 45 healthy donors, 25 patients with NSCLC and 41 HNC patients; (C) TGF-α levels (pg ml−1) in sera from 44 healthy donors, 25 patients with NSCLC and 34 HNC patients; (D) AR levels (pg ml−1) in sera from 45 healthy donors, 24 patients with NSCLC and 25 HNC patients. Values of sEGFR and its ligands followed a normal distribution. The continuous blue line represents the mean of the control group, whereas the dashed blue line shows the lower normal limit (mean−2s.d. of the control group) for sEGFR, EGF and AR and the upper normal limit (mean+2s.d. of the control group) for TGF-α.
Figure 2
Figure 2
ROCs for the combined levels of sEGFR, EGF and TGF-α when applied to the comparison of healthy donors and NSCLC patients by DA (A) and LR (B) or to the comparison of donors and HNC patients by DA (C) and LR (D).
See this image and copyright information in PMC

References

    1. Ayude D, Paez de la Cadena M, Cordero OJ, Nogueira M, Ayude J, Fernández-Briera A, Rodríguez-Berrocal FJ (2003–2004) Clinical interest of the combined use of serum CD26 and alpha-L-fucosidase in the early diagnosis of colorectal cancer. Dis Markers 19: 267–272 - PMC - PubMed
    1. Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Dachao L, Fishman DA, Podratz KC, Maihle NJ (2003) Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomark Prev 12: 103–113 - PubMed
    1. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Nita JM (1999) Serum sErbB1 and epidermal growth factor levels as tumour biomarkers in women with stage III o IV epithelial ovarian cancer. Cancer Epidemiol Biomark Prev 8: 129–137 - PubMed
    1. Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Perz EA, Maihle NJ (2001) A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomark Prev 10: 1175–1185 - PubMed
    1. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7: 2–8 - PubMed

Publication types